Search Results
Dame Roma Mitchell Cancer Research Laboratories School of Medicine, Adelaide Prostate Cancer Research Centre
School of Medicine Freemasons Foundation Centre for Men's Health, The University of Adelaide, Adelaide, South Australia 5005, Australia
Molecular Cancer Epidemiology Laboratory Genetics and Computational Biology Division, QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4006, Australia
Search for other papers by Shane Stegeman in
Google Scholar
PubMed
Dame Roma Mitchell Cancer Research Laboratories School of Medicine, Adelaide Prostate Cancer Research Centre
School of Medicine Freemasons Foundation Centre for Men's Health, The University of Adelaide, Adelaide, South Australia 5005, Australia
Molecular Cancer Epidemiology Laboratory Genetics and Computational Biology Division, QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4006, Australia
Search for other papers by Leire Moya in
Google Scholar
PubMed
Dame Roma Mitchell Cancer Research Laboratories School of Medicine, Adelaide Prostate Cancer Research Centre
School of Medicine Freemasons Foundation Centre for Men's Health, The University of Adelaide, Adelaide, South Australia 5005, Australia
Molecular Cancer Epidemiology Laboratory Genetics and Computational Biology Division, QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4006, Australia
School of Biomedical Sciences Institute of Health and Biomedical Innovation, Translational Research Institute Pty Ltd, Australian Prostate Cancer Research Centre – Queensland, Queensland University of Technology, 37 Kent Street, Woolloongabba, Brisbane, Queensland 4102, Australia
Dame Roma Mitchell Cancer Research Laboratories School of Medicine, Adelaide Prostate Cancer Research Centre
School of Medicine Freemasons Foundation Centre for Men's Health, The University of Adelaide, Adelaide, South Australia 5005, Australia
Molecular Cancer Epidemiology Laboratory Genetics and Computational Biology Division, QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4006, Australia
Search for other papers by Luke A Selth in
Google Scholar
PubMed
Dame Roma Mitchell Cancer Research Laboratories School of Medicine, Adelaide Prostate Cancer Research Centre
School of Medicine Freemasons Foundation Centre for Men's Health, The University of Adelaide, Adelaide, South Australia 5005, Australia
Molecular Cancer Epidemiology Laboratory Genetics and Computational Biology Division, QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4006, Australia
Search for other papers by Amanda B Spurdle in
Google Scholar
PubMed
Dame Roma Mitchell Cancer Research Laboratories School of Medicine, Adelaide Prostate Cancer Research Centre
School of Medicine Freemasons Foundation Centre for Men's Health, The University of Adelaide, Adelaide, South Australia 5005, Australia
Molecular Cancer Epidemiology Laboratory Genetics and Computational Biology Division, QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4006, Australia
Search for other papers by Judith A Clements in
Google Scholar
PubMed
Dame Roma Mitchell Cancer Research Laboratories School of Medicine, Adelaide Prostate Cancer Research Centre
School of Medicine Freemasons Foundation Centre for Men's Health, The University of Adelaide, Adelaide, South Australia 5005, Australia
Molecular Cancer Epidemiology Laboratory Genetics and Computational Biology Division, QIMR Berghofer Medical Research Institute, Brisbane, Queensland 4006, Australia
Search for other papers by Jyotsna Batra in
Google Scholar
PubMed
Introduction Globally, prostate cancer is the second most common cancer in men ( Siegel et al . 2014 ), with a significant proportion of cases attributed to heritable genetic conditions ( Siegel et al . 2014 ) that influence not only cancer
Department of Cancer Prevention Institute of Cancer Research
Department of Urology Oslo University Hospital, N-0424 Oslo, Norway
Search for other papers by Stefan J Barfeld in
Google Scholar
PubMed
Department of Cancer Prevention Institute of Cancer Research
Department of Urology Oslo University Hospital, N-0424 Oslo, Norway
Search for other papers by Harri M Itkonen in
Google Scholar
PubMed
Department of Cancer Prevention Institute of Cancer Research
Department of Urology Oslo University Hospital, N-0424 Oslo, Norway
Search for other papers by Alfonso Urbanucci in
Google Scholar
PubMed
Department of Cancer Prevention Institute of Cancer Research
Department of Urology Oslo University Hospital, N-0424 Oslo, Norway
Prostate Cancer Research Group Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, N-0318 Oslo, Norway
Department of Cancer Prevention Institute of Cancer Research
Department of Urology Oslo University Hospital, N-0424 Oslo, Norway
Prostate Cancer Research Group Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, N-0318 Oslo, Norway
Department of Cancer Prevention Institute of Cancer Research
Department of Urology Oslo University Hospital, N-0424 Oslo, Norway
Search for other papers by Ian G Mills in
Google Scholar
PubMed
) ( DeBerardinis et al . 2008 ). It is therefore not surprising that metabolic adaptations have been reported in various human cancers ( Hsu & Sabatini 2008 ). Metabolic status of the prostate gland and cancer predisposition The prostate gland is principally
Search for other papers by A Berruti in
Google Scholar
PubMed
Search for other papers by A Mosca in
Google Scholar
PubMed
Search for other papers by M Tucci in
Google Scholar
PubMed
Search for other papers by C Terrone in
Google Scholar
PubMed
Search for other papers by M Torta in
Google Scholar
PubMed
Search for other papers by R Tarabuzzi in
Google Scholar
PubMed
Search for other papers by L Russo in
Google Scholar
PubMed
Search for other papers by C Cracco in
Google Scholar
PubMed
Search for other papers by E Bollito in
Google Scholar
PubMed
Search for other papers by R M Scarpa in
Google Scholar
PubMed
Search for other papers by A Angeli in
Google Scholar
PubMed
Search for other papers by L Dogliotti in
Google Scholar
PubMed
Introduction Prostate cancer is frequent in the aging male population ( De Angelis et al. 1997 ). Androgen suppression by either orchiectomy or administration of luteinizing hormone-releasing hormone analogs (LHRH-As) is the
Search for other papers by Y Dong in
Google Scholar
PubMed
Search for other papers by L T Bui in
Google Scholar
PubMed
Search for other papers by D M Odorico in
Google Scholar
PubMed
Search for other papers by O L Tan in
Google Scholar
PubMed
Search for other papers by S A Myers in
Google Scholar
PubMed
Search for other papers by H Samaratunga in
Google Scholar
PubMed
Search for other papers by R A Gardiner in
Google Scholar
PubMed
Search for other papers by J A Clements in
Google Scholar
PubMed
Introduction Prostate cancer is the most common non-skin malignancy and the second leading cause of cancer death in males in the USA and other Western countries ( Jemal et al. 2004 ). Prostate-specific antigen (PSA), also known as
Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, British Columbia, Canada
Search for other papers by Alastair Davies in
Google Scholar
PubMed
Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, British Columbia, Canada
Search for other papers by Amina Zoubeidi in
Google Scholar
PubMed
Dame Roma Mitchell Cancer Research Laboratories and Freemasons Foundation Centre for Men’s Health, Adelaide Medical School, The University of Adelaide, Adelaide, South Australia, Australia
Search for other papers by Luke A Selth in
Google Scholar
PubMed
Introduction The androgen receptor (AR) is the principal driver of prostate cancer development and resistance; accordingly, AR pathway inhibitors (ARPIs) are used to treat men at all stages of the disease. Drug resistance ultimately ensues
Dame Roma Mitchell Cancer Research Laboratories, South Australian Health and Medical Research Institute, Adelaide Prostate Cancer Research Centre and Freemason's Foundation Centre for Men's Health, School of Medicine, University of Adelaide, Adelaide, Australia
Search for other papers by Margaret M Centenera in
Google Scholar
PubMed
Search for other papers by Sarah L Carter in
Google Scholar
PubMed
Dame Roma Mitchell Cancer Research Laboratories, South Australian Health and Medical Research Institute, Adelaide Prostate Cancer Research Centre and Freemason's Foundation Centre for Men's Health, School of Medicine, University of Adelaide, Adelaide, Australia
Search for other papers by Joanna L Gillis in
Google Scholar
PubMed
Search for other papers by Deborah L Marrocco-Tallarigo in
Google Scholar
PubMed
Search for other papers by Randall H Grose in
Google Scholar
PubMed
Search for other papers by Wayne D Tilley in
Google Scholar
PubMed
Dame Roma Mitchell Cancer Research Laboratories, South Australian Health and Medical Research Institute, Adelaide Prostate Cancer Research Centre and Freemason's Foundation Centre for Men's Health, School of Medicine, University of Adelaide, Adelaide, Australia
Search for other papers by Lisa M Butler in
Google Scholar
PubMed
Introduction Androgen deprivation therapy (ADT) is used palliatively to control tumor growth and metastasis in men with locally advanced prostate cancer ( Labrie 2011 ). Despite an initial response to ADT, the majority of patients will
Search for other papers by Varinder Jeet in
Google Scholar
PubMed
Search for other papers by Gregor Tevz in
Google Scholar
PubMed
Australian Prostate Cancer Research Centre – Queensland, Department of Urologic Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, Australia
Search for other papers by Melanie Lehman in
Google Scholar
PubMed
Search for other papers by Brett Hollier in
Google Scholar
PubMed
Australian Prostate Cancer Research Centre – Queensland, Department of Urologic Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, Brisbane, Australia
Search for other papers by Colleen Nelson in
Google Scholar
PubMed
Introduction Each year, more than 258 000 men will die of prostate cancer (PCa), making PCa the second largest cause of cancer-related mortality in males globally ( Jemal et al . 2011 , Siegel et al . 2012 ). While early-stage PCa can be
Search for other papers by Lisa K Philp in
Google Scholar
PubMed
Search for other papers by Anja Rockstroh in
Google Scholar
PubMed
Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada
Search for other papers by Melanie Lehman in
Google Scholar
PubMed
Search for other papers by Martin C Sadowski in
Google Scholar
PubMed
Search for other papers by Nenad Bartonicek in
Google Scholar
PubMed
School of Chemistry, University of Melbourne, Melbourne, Victoria, Australia
Search for other papers by John D Wade in
Google Scholar
PubMed
Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary
Search for other papers by Laszlo Otvos Jr in
Google Scholar
PubMed
Search for other papers by Colleen C Nelson in
Google Scholar
PubMed
, lipodystrophy and hypertension, irrespective of BMI. Prostate cancer (PCa) patients are reported to have lower circulating adiponectin compared to men with a non-malignant prostate ( Goktas et al. 2005 , Michalakis et al. 2007 , Arisan et al. 2009 ) and
Department of Surgery, The University of Melbourne, Parkville, Victoria, Australia
Division of Bioinformatics, Walter and Eliza Hall Institute, Parkville, Victoria, Australia
Search for other papers by Stefano Mangiola in
Google Scholar
PubMed
Search for other papers by Ryan Stuchbery in
Google Scholar
PubMed
Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
Diagnostic Genomics, NICTA, Victoria Research Laboratory, The University of Melbourne, Parkville, Victoria, Australia
Search for other papers by Geoff Macintyre in
Google Scholar
PubMed
Search for other papers by Michael J Clarkson in
Google Scholar
PubMed
Search for other papers by Justin S Peters in
Google Scholar
PubMed
Department of Surgery, The University of Melbourne, Parkville, Victoria, Australia
Department of Urology, Royal Melbourne Hospital, Parkville, Victoria, Australia
Search for other papers by Anthony J Costello in
Google Scholar
PubMed
Department of Surgery, The University of Melbourne, Parkville, Victoria, Australia
Department of Urology, Royal Melbourne Hospital, Parkville, Victoria, Australia
Search for other papers by Christopher M Hovens in
Google Scholar
PubMed
Department of Surgery, The University of Melbourne, Parkville, Victoria, Australia
Department of Urology, Royal Melbourne Hospital, Parkville, Victoria, Australia
Department of Urology, Frankston Hospital, Frankston, Victoria, Australia
Search for other papers by Niall M Corcoran in
Google Scholar
PubMed
Introduction Prostate cancer is the most widely diagnosed cancer among men in developed countries and the second most diagnosed cancer in men worldwide ( Torre et al . 2015 ). The widespread use of serum PSA measurement as an ad hoc community
Search for other papers by Lisa K Philp in
Google Scholar
PubMed
Search for other papers by Anja Rockstroh in
Google Scholar
PubMed
Search for other papers by Martin C Sadowski in
Google Scholar
PubMed
Search for other papers by Atefeh Taherian Fard in
Google Scholar
PubMed
Search for other papers by Melanie Lehman in
Google Scholar
PubMed
Search for other papers by Gregor Tevz in
Google Scholar
PubMed
Search for other papers by Michelle S Libério in
Google Scholar
PubMed
Search for other papers by Charles L Bidgood in
Google Scholar
PubMed
Search for other papers by Jennifer H Gunter in
Google Scholar
PubMed
Search for other papers by Stephen McPherson in
Google Scholar
PubMed
Search for other papers by Nenad Bartonicek in
Google Scholar
PubMed
School of Chemistry, University of Melbourne, Melbourne, Victoria, Australia
Search for other papers by John D Wade in
Google Scholar
PubMed
Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary
Search for other papers by Laszlo Otvos in
Google Scholar
PubMed
Search for other papers by Colleen C Nelson in
Google Scholar
PubMed
Introduction Prostate cancer (PCa) is androgen-dependent and consequently drugs inhibiting multiple facets of the androgen axis are used as therapeutics ( Harris et al. 2009 ). However, in advanced PCa, tumours develop mechanisms to escape